(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
(Title of each class) | ||
Exhibit No. | Exhibit | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the inline XBRL document). | |||||||
MALLINCKRODT PLC | ||||||||||||||
(registrant) | ||||||||||||||
Date: | March 10, 2021 | By: | /s/ Bryan M. Reasons | |||||||||||
Bryan M. Reasons | ||||||||||||||
Executive Vice President and Chief Financial Officer (principal financial officer) |
MALLINCKRODT PLC | |||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(unaudited, in millions, except per share data) | |||||||||||||||||
Three Months Ended | |||||||||||||||||
December 25, 2020 | Percent of Net sales | December 27, 2019 | Percent of Net sales | ||||||||||||||
Net sales | $ | 682.8 | 100.0 | % | $ | 804.9 | 100.0 | % | |||||||||
Cost of sales | 372.3 | 54.5 | 431.8 | 53.6 | |||||||||||||
Gross profit | 310.5 | 45.5 | 373.1 | 46.4 | |||||||||||||
Selling, general and administrative expenses | 200.9 | 29.4 | 169.2 | 21.0 | |||||||||||||
Research and development expenses | 65.0 | 9.5 | 81.4 | 10.1 | |||||||||||||
Restructuring charges, net | 21.7 | 3.2 | (12.9) | (1.6) | |||||||||||||
Non-restructuring impairment charges | — | — | 274.5 | 34.1 | |||||||||||||
(Gains) losses on divestiture | (6.5) | (1.0) | 33.5 | 4.2 | |||||||||||||
Opioid-related litigation settlement (gain) loss | (9.3) | (1.4) | 1,643.4 | 204.2 | |||||||||||||
Operating income (loss) | 38.7 | 5.7 | (1,816.0) | (225.6) | |||||||||||||
Interest expense | (60.2) | (8.8) | (77.2) | (9.6) | |||||||||||||
Interest income | 0.5 | 0.1 | 2.9 | 0.4 | |||||||||||||
Gain on debt extinguishment, net | — | — | 377.4 | 46.9 | |||||||||||||
Other income, net | 6.3 | 0.9 | 24.2 | 3.0 | |||||||||||||
Reorganization items, net | (61.4) | (9.0) | — | — | |||||||||||||
Loss from continuing operations before income taxes | (76.1) | (11.1) | (1,488.7) | (185.0) | |||||||||||||
Income tax expense (benefit) | 78.1 | 11.4 | (327.7) | (40.7) | |||||||||||||
Loss from continuing operations | (154.2) | (22.6) | (1,161.0) | (144.2) | |||||||||||||
Income from discontinued operations, net of income taxes | 1.3 | 0.2 | 3.9 | 0.5 | |||||||||||||
Net loss | $ | (152.9) | (22.4) | % | $ | (1,157.1) | (143.8) | % | |||||||||
Basic loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (1.82) | $ | (13.80) | |||||||||||||
Income from discontinued operations | 0.02 | 0.05 | |||||||||||||||
Net loss | $ | (1.81) | $ | (13.76) | |||||||||||||
Diluted loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (1.82) | $ | (13.80) | |||||||||||||
Income from discontinued operations | 0.02 | 0.05 | |||||||||||||||
Net loss | $ | (1.81) | $ | (13.76) | |||||||||||||
Weighted-average number of shares outstanding | |||||||||||||||||
Basic weighted-average shares outstanding | 84.6 | 84.1 | |||||||||||||||
Diluted weighted-average shares outstanding | 84.6 | 84.1 |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
CONSOLIDATED ADJUSTED EBITDA | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||||||||||||||||||||
Gross Profit | SG&A | R&D | Adjusted EBITDA | Gross Profit | SG&A | R&D | Adjusted EBITDA | ||||||||||||||||||||||
Net loss | $ | 310.5 | $ | 200.9 | $ | 65.0 | $ | (152.9) | $ | 373.1 | $ | 169.2 | $ | 81.4 | $ | (1,157.1) | |||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Interest expense, net | — | — | — | 59.7 | — | — | — | 74.3 | |||||||||||||||||||||
Income taxes | — | — | — | 78.1 | — | — | — | (327.7) | |||||||||||||||||||||
Depreciation(1) | 17.7 | (18.8) | (1.8) | 38.3 | 16.1 | (5.8) | (2.1) | 24.0 | |||||||||||||||||||||
Amortization | 170.6 | (0.8) | — | 171.4 | 202.8 | (0.8) | — | 203.6 | |||||||||||||||||||||
Restructuring charges, net | — | — | — | 21.7 | — | — | — | (12.9) | |||||||||||||||||||||
Non-restructuring impairment charge | — | — | — | — | — | — | — | 274.5 | |||||||||||||||||||||
Income from discontinued operations | — | — | — | (1.3) | — | — | — | (3.9) | |||||||||||||||||||||
Change in contingent consideration fair value | — | (7.5) | — | 7.5 | — | 36.7 | — | (36.7) | |||||||||||||||||||||
Significant legal and environmental charges (2) | 0.9 | (2.6) | — | (5.8) | — | — | — | 1,643.4 | |||||||||||||||||||||
(Gains) losses on divestiture | — | — | — | (6.5) | — | — | — | 33.5 | |||||||||||||||||||||
Separation costs | — | (18.4) | — | 18.4 | — | (13.5) | — | 13.5 | |||||||||||||||||||||
Gains on debt extinguishment, net | — | — | — | — | — | — | — | (377.4) | |||||||||||||||||||||
Unrealized gain on equity investment | — | — | — | (1.6) | — | — | — | (13.7) | |||||||||||||||||||||
Reorganization items, net | — | — | — | 61.4 | — | — | — | — | |||||||||||||||||||||
Share-based compensation | 0.4 | (6.0) | (1.3) | 7.7 | 0.2 | (2.6) | (0.4) | 3.2 | |||||||||||||||||||||
As adjusted: | $ | 500.1 | $ | 146.8 | $ | 61.9 | $ | 296.1 | $ | 592.2 | $ | 183.2 | $ | 78.9 | $ | 340.6 | |||||||||||||
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
SEGMENT OPERATING INCOME (1) | |||||||||||
(unaudited, in millions) | |||||||||||
Three Months Ended | |||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||
Specialty Brands | $ | 250.7 | $ | 315.9 | |||||||
Specialty Generics | 50.9 | 43.1 | |||||||||
Segment operating income | 301.6 | 359.0 | |||||||||
Unallocated amounts: | |||||||||||
Corporate and unallocated expenses (2) | (13.8) | (25.7) | |||||||||
Depreciation and amortization | (209.7) | (227.6) | |||||||||
Share-based compensation | (7.7) | (3.2) | |||||||||
Restructuring charges, net | (21.7) | 12.9 | |||||||||
Non-restructuring impairment charges | — | (274.5) | |||||||||
Separation costs | (18.4) | (13.5) | |||||||||
Opioid-related litigation settlement gain (loss) | 9.3 | (1,643.4) | |||||||||
Medicaid lawsuit | (0.9) | — | |||||||||
Operating income (loss) | $ | 38.7 | $ | (1,816.0) |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | $ | 506.6 | $ | 611.4 | (17.1) | % | 0.1 | % | (17.2) | % | |||||||||||||||||||
Specialty Generics | 177.1 | 193.5 | (8.5) | — | (8.5) | ||||||||||||||||||||||||
Segment net sales | 683.7 | 804.9 | (15.1) | 0.1 | (15.2) | ||||||||||||||||||||||||
Medicaid lawsuit | (0.9) | — | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 682.8 | $ | 804.9 | (15.2) | % | 0.1 | % | (15.3) | % |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | |||||||||||||||||||||||||||||
Acthar Gel | $ | 191.3 | $ | 232.6 | (17.8) | % | — | % | (17.8) | % | |||||||||||||||||||
INOmax | 135.6 | 143.8 | (5.7) | 0.1 | (5.8) | ||||||||||||||||||||||||
Ofirmev | 60.5 | 111.8 | (45.9) | — | (45.9) | ||||||||||||||||||||||||
Therakos | 64.5 | 63.3 | 1.9 | 1.2 | 0.7 | ||||||||||||||||||||||||
Amitiza | 50.6 | 50.9 | (0.6) | — | (0.6) | ||||||||||||||||||||||||
Other | 4.1 | 9.0 | (54.4) | — | (54.4) | ||||||||||||||||||||||||
Specialty Brands Total | 506.6 | 611.4 | (17.1) | 0.1 | (17.2) | ||||||||||||||||||||||||
Specialty Generics | |||||||||||||||||||||||||||||
Hydrocodone (API) and hydrocodone-containing tablets | 26.1 | 25.1 | 4.0 | — | 4.0 | ||||||||||||||||||||||||
Oxycodone (API) and oxycodone-containing tablets | 20.4 | 21.6 | (5.6) | — | (5.6) | ||||||||||||||||||||||||
Acetaminophen (API) | 58.5 | 46.8 | 25.0 | — | 25.0 | ||||||||||||||||||||||||
Other controlled substances | 66.1 | 86.8 | (23.8) | — | (23.8) | ||||||||||||||||||||||||
Other | 6.0 | 13.2 | (54.5) | — | (54.5) | ||||||||||||||||||||||||
Specialty Generics Total | 177.1 | 193.5 | (8.5) | — | (8.5) | ||||||||||||||||||||||||
Segment net sales | 683.7 | 804.9 | (15.1) | 0.1 | (15.2) | ||||||||||||||||||||||||
Medicaid lawsuit | (0.9) | — | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 682.8 | $ | 804.9 | (15.2) | % | 0.1 | % | (15.3) | % |
MALLINCKRODT PLC | |||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||
(unaudited, in millions, except per share data) | |||||||||||||||||
Fiscal Year | |||||||||||||||||
December 25, 2020 | Percent of Net sales | December 27, 2019 | Percent of Net sales | ||||||||||||||
Net sales (includes refined estimate of the retrospective one-time charge of $536.0 related to the Medicaid lawsuit for the fiscal year ended December 25, 2020) | $ | 2,213.4 | 100.0 | % | $ | 3,162.5 | 100.0 | % | |||||||||
Cost of sales | 1,544.0 | 69.8 | 1,741.1 | 55.1 | |||||||||||||
Gross profit | 669.4 | 30.2 | 1,421.4 | 44.9 | |||||||||||||
Selling, general and administrative expenses | 884.1 | 39.9 | 831.0 | 26.3 | |||||||||||||
Research and development expenses | 290.8 | 13.1 | 349.4 | 11.0 | |||||||||||||
Restructuring charges, net | 37.5 | 1.7 | (1.7) | (0.1) | |||||||||||||
Non-restructuring impairment charges | 63.5 | 2.9 | 388.0 | 12.3 | |||||||||||||
(Gains) losses on divestiture | (16.6) | (0.7) | 33.5 | 1.1 | |||||||||||||
Opioid-related litigation settlement (gain) loss | (43.4) | (2.0) | 1,643.4 | 52.0 | |||||||||||||
Medicaid lawsuit | 105.1 | 4.7 | — | — | |||||||||||||
Operating loss | (651.6) | (29.4) | (1,822.2) | (57.6) | |||||||||||||
Interest expense | (261.1) | (11.8) | (309.0) | (9.8) | |||||||||||||
Interest income | 5.9 | 0.3 | 9.5 | 0.3 | |||||||||||||
Gains on debt extinguishment, net | — | — | 466.6 | 14.8 | |||||||||||||
Other income, net | 7.4 | 0.3 | 63.6 | 2.0 | |||||||||||||
Reorganization items, net | (61.4) | (2.8) | — | — | |||||||||||||
Loss from continuing operations before income taxes | (960.8) | (43.4) | (1,591.5) | (50.3) | |||||||||||||
Income tax expense (benefit) | 8.9 | 0.4 | (584.3) | (18.5) | |||||||||||||
Loss from continuing operations | (969.7) | (43.8) | (1,007.2) | (31.8) | |||||||||||||
Income from discontinued operations, net of income taxes | 25.1 | 1.1 | 10.7 | 0.3 | |||||||||||||
Net loss | $ | (944.6) | (42.7) | % | $ | (996.5) | (31.5) | % | |||||||||
Basic loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (11.48) | $ | (12.00) | |||||||||||||
Income from discontinued operations | 0.30 | 0.13 | |||||||||||||||
Net loss | $ | (11.18) | $ | (11.88) | |||||||||||||
Diluted loss per share: | |||||||||||||||||
Loss from continuing operations | $ | (11.48) | $ | (12.00) | |||||||||||||
Income from discontinued operations | 0.30 | 0.13 | |||||||||||||||
Net loss | $ | (11.18) | $ | (11.88) | |||||||||||||
Weighted-average number of shares outstanding: | |||||||||||||||||
Basic | 84.5 | 83.9 | |||||||||||||||
Diluted | 84.5 | 83.9 | |||||||||||||||
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
CONSOLIDATED ADJUSTED EBITDA | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Fiscal Year | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||||||||||||||||||||
Gross Profit | SG&A | R&D | Adjusted EBITDA | Gross Profit | SG&A | R&D | Adjusted EBITDA | ||||||||||||||||||||||
Net loss | $ | 669.4 | $ | 884.1 | $ | 290.8 | $ | (944.6) | $ | 1,421.4 | $ | 831.0 | $ | 349.4 | $ | (996.5) | |||||||||||||
Adjustments: | |||||||||||||||||||||||||||||
Interest expense, net | — | — | — | 255.2 | — | — | — | 299.5 | |||||||||||||||||||||
Income taxes | — | — | — | 8.9 | — | — | — | (584.3) | |||||||||||||||||||||
Depreciation(1) | 71.9 | (35.1) | (7.0) | 114.0 | 67.7 | (22.2) | (7.8) | 97.7 | |||||||||||||||||||||
Amortization | 767.8 | (3.4) | — | 771.2 | 847.9 | (5.5) | — | 853.4 | |||||||||||||||||||||
Restructuring charges, net | — | — | — | 37.5 | — | — | — | (1.7) | |||||||||||||||||||||
Non-restructuring impairment charge | — | — | — | 63.5 | — | — | — | 388.0 | |||||||||||||||||||||
Inventory step-up expense | — | — | — | — | 10.0 | — | — | 10.0 | |||||||||||||||||||||
Income from discontinued operations | — | — | — | (25.1) | — | — | — | (10.7) | |||||||||||||||||||||
Change in contingent consideration fair value | — | (9.9) | — | 9.9 | — | 60.2 | — | (60.2) | |||||||||||||||||||||
Significant legal and environmental charges (2) | 536.0 | (55.7) | — | 653.4 | — | (28.2) | — | 1,671.6 | |||||||||||||||||||||
(Gains) losses on divestiture | — | — | — | (16.6) | — | — | — | 33.5 | |||||||||||||||||||||
Separation costs | — | (93.4) | — | 93.4 | — | (63.9) | — | 63.9 | |||||||||||||||||||||
Gain on debt extinguishment, net | — | — | — | — | — | — | — | (466.6) | |||||||||||||||||||||
Unrealized gain on equity investment | — | — | — | (3.8) | — | — | — | (20.2) | |||||||||||||||||||||
R&D upfront payment | — | — | (5.0) | 5.0 | — | — | (20.0) | 20.0 | |||||||||||||||||||||
Reorganization items, net | — | — | — | 61.4 | — | — | — | — | |||||||||||||||||||||
Share-based compensation | 1.3 | (19.9) | (4.1) | 25.3 | 1.9 | (26.7) | (5.2) | 33.8 | |||||||||||||||||||||
As adjusted: | $ | 2,046.4 | $ | 666.7 | $ | 274.7 | $ | 1,108.6 | $ | 2,348.9 | $ | 744.7 | $ | 316.4 | $ | 1,331.2 | |||||||||||||
1300000 | -19900000 | -4100000 |
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
SEGMENT OPERATING INCOME (1) | |||||||||||
(unaudited, in millions) | |||||||||||
Fiscal Year | |||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||
Specialty Brands | $ | 1,015.7 | $ | 1,210.1 | |||||||
Specialty Generics | 206.4 | 168.5 | |||||||||
Segment operating income | 1,222.1 | 1,378.6 | |||||||||
Unallocated amounts: | |||||||||||
Corporate and unallocated expenses (2) | (166.1) | (102.3) | |||||||||
Depreciation and amortization | (885.2) | (951.1) | |||||||||
Share-based compensation | (25.3) | (33.8) | |||||||||
Restructuring charges, net | (37.5) | 1.7 | |||||||||
Non-restructuring impairment charges | (63.5) | (388.0) | |||||||||
Separation costs | (93.4) | (63.9) | |||||||||
R&D upfront payment | (5.0) | (20.0) | |||||||||
Opioid-related litigation settlement gain (loss) | 43.4 | (1,643.4) | |||||||||
Medicaid lawsuit | (641.1) | — | |||||||||
Operating loss | $ | (651.6) | $ | (1,822.2) |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Fiscal Year | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | $ | 2,059.6 | $ | 2,423.8 | (15.0) | % | — | % | (15.0) | % | |||||||||||||||||||
Specialty Generics | 689.8 | 738.7 | (6.6) | — | (6.6) | ||||||||||||||||||||||||
Segment net sales | 2,749.4 | 3,162.5 | (13.1) | — | (13.1) | ||||||||||||||||||||||||
Medicaid lawsuit | (536.0) | — | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 2,213.4 | $ | 3,162.5 | (30.0) | % | — | % | (30.0) | % |
MALLINCKRODT PLC | |||||||||||||||||||||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||||||||||||||||||||
SELECT PRODUCT LINE NET SALES | |||||||||||||||||||||||||||||
(unaudited, in millions) | |||||||||||||||||||||||||||||
Fiscal Year | |||||||||||||||||||||||||||||
December 25, 2020 | December 27, 2019 | Percent change | Currency impact | Constant-currency growth | |||||||||||||||||||||||||
Specialty Brands | |||||||||||||||||||||||||||||
Acthar | $ | 767.9 | $ | 952.7 | (19.4) | % | — | % | (19.4) | % | |||||||||||||||||||
Inomax | 574.1 | 571.4 | 0.5 | — | 0.5 | ||||||||||||||||||||||||
Ofirmev | 276.5 | 384.0 | (28.0) | — | (28.0) | ||||||||||||||||||||||||
Therakos | 238.6 | 246.9 | (3.4) | 0.3 | (3.7) | ||||||||||||||||||||||||
Amitiza | 188.8 | 208.5 | (9.4) | — | (9.4) | ||||||||||||||||||||||||
Other | 13.7 | 60.3 | (77.3) | — | (77.3) | ||||||||||||||||||||||||
Specialty Brands Total | 2,059.6 | 2,423.8 | (15.0) | — | (15.0) | ||||||||||||||||||||||||
Specialty Generics | |||||||||||||||||||||||||||||
Hydrocodone (API) and hydrocodone-containing tablets | 98.0 | 76.3 | 28.4 | — | 28.4 | ||||||||||||||||||||||||
Oxycodone (API) and oxycodone-containing tablets | 68.4 | 74.9 | (8.7) | — | (8.7) | ||||||||||||||||||||||||
Acetaminophen (API) | 213.0 | 189.9 | 12.2 | — | 12.2 | ||||||||||||||||||||||||
Other controlled substances | 289.9 | 352.5 | (17.8) | — | (17.8) | ||||||||||||||||||||||||
Other | 20.5 | 45.1 | (54.5) | — | (54.5) | ||||||||||||||||||||||||
Specialty Generics Total | 689.8 | 738.7 | (6.6) | — | (6.6) | ||||||||||||||||||||||||
Segment net sales | 2,749.4 | 3,162.5 | (13.1) | — | (13.1) | ||||||||||||||||||||||||
Medicaid lawsuit | 536.0 | — | * | * | * | ||||||||||||||||||||||||
Net sales | $ | 2,213.4 | $ | 3,162.5 | (30.0) | % | — | % | (30.0) | % |
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
(unaudited, in millions) | |||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||
Assets | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ | 1,070.6 | $ | 790.9 | |||||||
Accounts receivable, net | 538.8 | 577.5 | |||||||||
Inventories | 344.9 | 312.1 | |||||||||
Prepaid expenses and other current assets | 350.0 | 150.2 | |||||||||
Total current assets | 2,304.3 | 1,830.7 | |||||||||
Property, plant and equipment, net | 833.1 | 896.5 | |||||||||
Intangible assets, net | 6,184.5 | 7,018.0 | |||||||||
Other assets | 393.5 | 593.7 | |||||||||
Total Assets | $ | 9,715.4 | $ | 10,338.9 | |||||||
Liabilities and Shareholders' Equity | |||||||||||
Current Liabilities: | |||||||||||
Current maturities of long-term debt | $ | 3,587.9 | $ | 633.6 | |||||||
Accounts payable | 93.3 | 139.8 | |||||||||
Accrued payroll and payroll-related costs | 79.4 | 105.2 | |||||||||
Accrued interest | 26.9 | 62.9 | |||||||||
Accrued and other current liabilities | 331.2 | 485.4 | |||||||||
Total current liabilities | 4,118.7 | 1,426.9 | |||||||||
Long-term debt | — | 4,741.2 | |||||||||
Opioid-related litigation settlement liability | — | 1,643.4 | |||||||||
Pension and postretirement benefits | 34.6 | 62.4 | |||||||||
Environmental liabilities | 59.8 | 60.0 | |||||||||
Deferred income taxes | 80.6 | 11.0 | |||||||||
Other income tax liabilities | 100.1 | 227.1 | |||||||||
Other liabilities | 109.8 | 226.2 | |||||||||
Liabilities subject to compromise | 4,192.6 | — | |||||||||
Total Liabilities | 8,696.2 | 8,398.2 | |||||||||
Shareholders' Equity: | |||||||||||
Preferred shares | — | — | |||||||||
Ordinary shares | 18.8 | 18.7 | |||||||||
Ordinary shares held in treasury at cost | (1,616.1) | (1,615.7) | |||||||||
Additional paid-in capital | 5,587.6 | 5,562.5 | |||||||||
Retained deficit | (2,961.5) | (2,016.9) | |||||||||
Accumulated other comprehensive loss | (9.6) | (7.9) | |||||||||
Total Shareholders' Equity | 1,019.2 | 1,940.7 | |||||||||
Total Liabilities and Shareholders' Equity | $ | 9,715.4 | $ | 10,338.9 |
MALLINCKRODT PLC | |||||||||||
(DEBTOR-IN-POSSESSION) | |||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
(unaudited, in millions) | |||||||||||
Fiscal Year | |||||||||||
December 25, 2020 | December 27, 2019 | ||||||||||
Cash Flows From Operating Activities: | |||||||||||
Net loss | $ | (944.6) | $ | (996.5) | |||||||
Adjustments to reconcile net cash from operating activities: | |||||||||||
Depreciation and amortization | 885.2 | 951.1 | |||||||||
Share-based compensation | 25.3 | 33.8 | |||||||||
Deferred income taxes | 385.3 | (604.3) | |||||||||
Non-cash impairment charges | 63.5 | 388.0 | |||||||||
Inventory provisions | 18.5 | 18.0 | |||||||||
(Gains) losses on divestiture | (16.6) | 33.5 | |||||||||
Gain on repurchase of debt | — | (466.6) | |||||||||
Other non-cash items | (40.2) | (65.7) | |||||||||
Reorganization items, net | 10.2 | — | |||||||||
Changes in assets and liabilities: | |||||||||||
Accounts receivable, net | 37.9 | 31.6 | |||||||||
Inventories | (51.1) | (23.1) | |||||||||
Accounts payable | 15.7 | 6.7 | |||||||||
Income taxes | (433.8) | (2.1) | |||||||||
Opioid-related litigation settlement liability | — | 1,600.0 | |||||||||
Medicaid lawsuit | 638.9 | — | |||||||||
Other | (95.3) | (161.5) | |||||||||
Net cash from operating activities | 498.9 | 742.9 | |||||||||
Cash Flows From Investing Activities: | |||||||||||
Capital expenditures | (47.7) | (133.0) | |||||||||
Proceeds from divestiture, net of cash | (0.7) | 95.1 | |||||||||
Other | 37.2 | 29.6 | |||||||||
Net cash from investing activities | (11.2) | (8.3) | |||||||||
Cash Flows From Financing Activities: | |||||||||||
Issuance of external debt | — | 695.0 | |||||||||
Repayment of external debt | (139.5) | (945.1) | |||||||||
Debt financing costs | (9.4) | (10.1) | |||||||||
Proceeds from exercise of share options | — | 0.6 | |||||||||
Repurchase of shares | (0.4) | (2.6) | |||||||||
Other | (36.3) | (17.9) | |||||||||
Net cash from financing activities | (185.6) | (280.1) | |||||||||
Effect of currency rate changes on cash | 2.3 | 0.6 | |||||||||
Net change in cash, cash equivalents and restricted cash | 304.4 | 455.1 | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 822.6 | 367.5 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 1,127.0 | $ | 822.6 | |||||||
Cash and cash equivalents at end of period | $ | 1,070.6 | $ | 790.9 | |||||||
Restricted cash included in prepaid expenses and other assets at end of period | 20.2 | — | |||||||||
Restricted cash included in other long-term assets at end of period | 36.2 | 31.7 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 1,127.0 | $ | 822.6 |